Click for best price
Intratumoral Cancer Therapies Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Intratumoral Cancer Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intratumoral Cancer Therapies. This report contains market size and forecasts of Intratumoral Cancer Therapies in global, including the following market information:
Global Intratumoral Cancer Therapies Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Intratumoral Cancer Therapies market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monoclonal Antibodies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Intratumoral Cancer Therapies include Amgen, AstraZeneca, Bayer AG, Bristol-Myers Squibb, Pfizer, Novarts AG, Johnson & Johnson, Eli Lilly and F. Hoffmann-la Roche, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Intratumoral Cancer Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Intratumoral Cancer Therapies Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Intratumoral Cancer Therapies Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immune System Modulators
Adoptive Cell Transfer
Cytokines
Global Intratumoral Cancer Therapies Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Intratumoral Cancer Therapies Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer Research Centres
Clinics
Global Intratumoral Cancer Therapies Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Intratumoral Cancer Therapies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Intratumoral Cancer Therapies revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Intratumoral Cancer Therapies revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AstraZeneca
Bayer AG
Bristol-Myers Squibb
Pfizer
Novarts AG
Johnson & Johnson
Eli Lilly
F. Hoffmann-la Roche
Seattle Genetics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Intratumoral Cancer Therapies, market overview.
Chapter 2: Global Intratumoral Cancer Therapies market size in revenue.
Chapter 3: Detailed analysis of Intratumoral Cancer Therapies company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Intratumoral Cancer Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Intratumoral Cancer Therapies Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
64 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Intratumoral Cancer Therapies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Intratumoral Cancer Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Intratumoral Cancer Therapies Overall Market Size
2.1 Global Intratumoral Cancer Therapies Market Size: 2022 VS 2029
2.2 Global Intratumoral Cancer Therapies Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Intratumoral Cancer Therapies Players in Global Market
3.2 Top Global Intratumoral Cancer Therapies Companies Ranked by Revenue
3.3 Global Intratumoral Cancer Therapies Revenue by Companies
3.4 Top 3 and Top 5 Intratumoral Cancer Therapies Companies in Global Market, by Revenue in 2022
3.5 Global Companies Intratumoral Cancer Therapies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Intratumoral Cancer Therapies Players in Global Market
3.6.1 List of Global Tier 1 Intratumoral Cancer Therapies Companies
3.6.2 List of Global Tier 2 and Tier 3 Intratumoral Cancer Therapies Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Intratumoral Cancer Therapies Market Size Markets, 2022 & 2029
4.1.2 Monoclonal Antibodies
4.1.3 Vaccines
4.1.4 Checkpoint Inhibitors
4.1.5 Cell Therapies
4.1.6 Immune System Modulators
4.1.7 Adoptive Cell Transfer
4.1.8 Cytokines
4.2 By Type - Global Intratumoral Cancer Therapies Revenue & Forecasts
4.2.1 By Type - Global Intratumoral Cancer Therapies Revenue, 2018-2023
4.2.2 By Type - Global Intratumoral Cancer Therapies Revenue, 2024-2029
4.2.3 By Type - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Intratumoral Cancer Therapies Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Cancer Research Centres
5.1.4 Clinics
5.2 By Application - Global Intratumoral Cancer Therapies Revenue & Forecasts
5.2.1 By Application - Global Intratumoral Cancer Therapies Revenue, 2018-2023
5.2.2 By Application - Global Intratumoral Cancer Therapies Revenue, 2024-2029
5.2.3 By Application - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Intratumoral Cancer Therapies Market Size, 2022 & 2029
6.2 By Region - Global Intratumoral Cancer Therapies Revenue & Forecasts
6.2.1 By Region - Global Intratumoral Cancer Therapies Revenue, 2018-2023
6.2.2 By Region - Global Intratumoral Cancer Therapies Revenue, 2024-2029
6.2.3 By Region - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Intratumoral Cancer Therapies Revenue, 2018-2029
6.3.2 US Intratumoral Cancer Therapies Market Size, 2018-2029
6.3.3 Canada Intratumoral Cancer Therapies Market Size, 2018-2029
6.3.4 Mexico Intratumoral Cancer Therapies Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Intratumoral Cancer Therapies Revenue, 2018-2029
6.4.2 Germany Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.3 France Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.4 U.K. Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.5 Italy Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.6 Russia Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.7 Nordic Countries Intratumoral Cancer Therapies Market Size, 2018-2029
6.4.8 Benelux Intratumoral Cancer Therapies Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Intratumoral Cancer Therapies Revenue, 2018-2029
6.5.2 China Intratumoral Cancer Therapies Market Size, 2018-2029
6.5.3 Japan Intratumoral Cancer Therapies Market Size, 2018-2029
6.5.4 South Korea Intratumoral Cancer Therapies Market Size, 2018-2029
6.5.5 Southeast Asia Intratumoral Cancer Therapies Market Size, 2018-2029
6.5.6 India Intratumoral Cancer Therapies Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Intratumoral Cancer Therapies Revenue, 2018-2029
6.6.2 Brazil Intratumoral Cancer Therapies Market Size, 2018-2029
6.6.3 Argentina Intratumoral Cancer Therapies Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Intratumoral Cancer Therapies Revenue, 2018-2029
6.7.2 Turkey Intratumoral Cancer Therapies Market Size, 2018-2029
6.7.3 Israel Intratumoral Cancer Therapies Market Size, 2018-2029
6.7.4 Saudi Arabia Intratumoral Cancer Therapies Market Size, 2018-2029
6.7.5 UAE Intratumoral Cancer Therapies Market Size, 2018-2029
7 Intratumoral Cancer Therapies Companies Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Intratumoral Cancer Therapies Major Product Offerings
7.1.4 Amgen Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Intratumoral Cancer Therapies Major Product Offerings
7.2.4 AstraZeneca Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Bayer AG
7.3.1 Bayer AG Company Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Intratumoral Cancer Therapies Major Product Offerings
7.3.4 Bayer AG Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.3.5 Bayer AG Key News & Latest Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Intratumoral Cancer Therapies Major Product Offerings
7.4.4 Bristol-Myers Squibb Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.4.5 Bristol-Myers Squibb Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Intratumoral Cancer Therapies Major Product Offerings
7.5.4 Pfizer Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Novarts AG
7.6.1 Novarts AG Company Summary
7.6.2 Novarts AG Business Overview
7.6.3 Novarts AG Intratumoral Cancer Therapies Major Product Offerings
7.6.4 Novarts AG Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.6.5 Novarts AG Key News & Latest Developments
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Company Summary
7.7.2 Johnson & Johnson Business Overview
7.7.3 Johnson & Johnson Intratumoral Cancer Therapies Major Product Offerings
7.7.4 Johnson & Johnson Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.7.5 Johnson & Johnson Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Intratumoral Cancer Therapies Major Product Offerings
7.8.4 Eli Lilly Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 F. Hoffmann-la Roche
7.9.1 F. Hoffmann-la Roche Company Summary
7.9.2 F. Hoffmann-la Roche Business Overview
7.9.3 F. Hoffmann-la Roche Intratumoral Cancer Therapies Major Product Offerings
7.9.4 F. Hoffmann-la Roche Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.9.5 F. Hoffmann-la Roche Key News & Latest Developments
7.10 Seattle Genetics
7.10.1 Seattle Genetics Company Summary
7.10.2 Seattle Genetics Business Overview
7.10.3 Seattle Genetics Intratumoral Cancer Therapies Major Product Offerings
7.10.4 Seattle Genetics Intratumoral Cancer Therapies Revenue in Global Market (2018-2023)
7.10.5 Seattle Genetics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Intratumoral Cancer Therapies Market Opportunities & Trends in Global Market
Table 2. Intratumoral Cancer Therapies Market Drivers in Global Market
Table 3. Intratumoral Cancer Therapies Market Restraints in Global Market
Table 4. Key Players of Intratumoral Cancer Therapies in Global Market
Table 5. Top Intratumoral Cancer Therapies Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Intratumoral Cancer Therapies Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Intratumoral Cancer Therapies Revenue Share by Companies, 2018-2023
Table 8. Global Companies Intratumoral Cancer Therapies Product Type
Table 9. List of Global Tier 1 Intratumoral Cancer Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Intratumoral Cancer Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Intratumoral Cancer Therapies Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Intratumoral Cancer Therapies Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Intratumoral Cancer Therapies Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Intratumoral Cancer Therapies Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Intratumoral Cancer Therapies Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Intratumoral Cancer Therapies Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Intratumoral Cancer Therapies Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Intratumoral Cancer Therapies Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Intratumoral Cancer Therapies Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Intratumoral Cancer Therapies Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Intratumoral Cancer Therapies Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Intratumoral Cancer Therapies Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Intratumoral Cancer Therapies Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Intratumoral Cancer Therapies Revenue, (US$, Mn), 2024-2029
Table 30. Amgen Company Summary
Table 31. Amgen Intratumoral Cancer Therapies Product Offerings
Table 32. Amgen Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 33. Amgen Key News & Latest Developments
Table 34. AstraZeneca Company Summary
Table 35. AstraZeneca Intratumoral Cancer Therapies Product Offerings
Table 36. AstraZeneca Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 37. AstraZeneca Key News & Latest Developments
Table 38. Bayer AG Company Summary
Table 39. Bayer AG Intratumoral Cancer Therapies Product Offerings
Table 40. Bayer AG Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 41. Bayer AG Key News & Latest Developments
Table 42. Bristol-Myers Squibb Company Summary
Table 43. Bristol-Myers Squibb Intratumoral Cancer Therapies Product Offerings
Table 44. Bristol-Myers Squibb Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 45. Bristol-Myers Squibb Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Intratumoral Cancer Therapies Product Offerings
Table 48. Pfizer Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Novarts AG Company Summary
Table 51. Novarts AG Intratumoral Cancer Therapies Product Offerings
Table 52. Novarts AG Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 53. Novarts AG Key News & Latest Developments
Table 54. Johnson & Johnson Company Summary
Table 55. Johnson & Johnson Intratumoral Cancer Therapies Product Offerings
Table 56. Johnson & Johnson Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 57. Johnson & Johnson Key News & Latest Developments
Table 58. Eli Lilly Company Summary
Table 59. Eli Lilly Intratumoral Cancer Therapies Product Offerings
Table 60. Eli Lilly Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 61. Eli Lilly Key News & Latest Developments
Table 62. F. Hoffmann-la Roche Company Summary
Table 63. F. Hoffmann-la Roche Intratumoral Cancer Therapies Product Offerings
Table 64. F. Hoffmann-la Roche Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 65. F. Hoffmann-la Roche Key News & Latest Developments
Table 66. Seattle Genetics Company Summary
Table 67. Seattle Genetics Intratumoral Cancer Therapies Product Offerings
Table 68. Seattle Genetics Intratumoral Cancer Therapies Revenue (US$, Mn) & (2018-2023)
Table 69. Seattle Genetics Key News & Latest Developments
List of Figures
Figure 1. Intratumoral Cancer Therapies Segment by Type in 2022
Figure 2. Intratumoral Cancer Therapies Segment by Application in 2022
Figure 3. Global Intratumoral Cancer Therapies Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Intratumoral Cancer Therapies Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Intratumoral Cancer Therapies Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Intratumoral Cancer Therapies Revenue in 2022
Figure 8. By Type - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 9. By Application - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 10. By Type - Global Intratumoral Cancer Therapies Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 12. By Application - Global Intratumoral Cancer Therapies Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 14. By Region - Global Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 15. By Country - North America Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 16. US Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 20. Germany Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 21. France Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 28. China Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 32. India Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 34. Brazil Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Intratumoral Cancer Therapies Revenue Market Share, 2018-2029
Figure 37. Turkey Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Intratumoral Cancer Therapies Revenue, (US$, Mn), 2018-2029
Figure 41. Amgen Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AstraZeneca Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bayer AG Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bristol-Myers Squibb Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novarts AG Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Johnson & Johnson Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Eli Lilly Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. F. Hoffmann-la Roche Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Seattle Genetics Intratumoral Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
